Stay Ahead

712 North Inc. obtains a new patent.

712 North Inc., a California-based pharmaceutical company, announced on May 28, 2024, that a new patent entitled 'Pyranone compounds useful to modulate OMA1 protease' was granted by the United States Patent and Trademark Office (USPTO).

712 North develops personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases. For more information, please visit www.712north.com.

712 North Inc. publishes a new study in BBA – Molecular Cell Research.

712 North Inc., a California-based pharmaceutical company, announced on August 13, 2021, the publication of a new research study entitled ‘Tau phosphorylation and OPA1 proteolysis are unrelated events: Implications for Alzheimer's Disease’ in BBA – Molecular Cell Research.

The study investigates the functional interaction between tau and the OPA1/OMA1 pathway. Dr. Alavi, 712 North’s CEO, said, “I am excited to share my results with the research community. We knew about mitochondrial impairments in Alzheimer’s for half a century. This study is a first step to understand the role of deteriorating mitochondria in Alzheimer’s disease.”

The study was supported by the National Institute on Aging (NIA). 712 North develops personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases. For more information, please visit www.712north.com.

712 North Inc. publishes a new OMA1 model in BBA – Proteins and Proteomics.

712 North Inc., a California-based pharmaceutical company, announced on October 29, 2020, the publication of a new research study entitled ‘OMA1—An integral membrane protease?’ in BBA – Proteins and Proteomics.

Dr. Marcel V. Alavi, 712 North’s CEO, said, “The prevailing opinion in the field is that OMA1 is anchored to the inner membrane. But our OMA1 homology model suggests that OMA1 actually is an integral membrane protease, which is quite a paradigm shift.” The study was supported by the National Institute on Aging (NIA). 712 North develops personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases. For more information, please visit www.712north.com.

712 North Inc. joins the QB3 Garage at UC Berkeley.

712 North Inc., a discovery-stage therapeutics company, announced on July 1, 2019, that the company has joined the QB3 Garage at UC Berkeley. QB3 is a life science incubator created by the University of California to support innovation and entrepreneurship. QB3 offers lab space at different sites across the San Francisco Bay Area.

712 North develops personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases. The company is supported by a Small Business Innovation Research (SBIR) grant awarded by the National Institute on Aging (NIA). Dr. Marcel V. Alavi, 712 North’s CEO, said, “Our new lab on the UC Berkeley campus is ideal because it is a great community with many potential partners and collaborators.” For more information, please visit www.712north.com.

712 North Inc. receives SBIR grant from the NIA

712 North Inc. announced on March 30, 2019 that the National Institute on Aging (NIA) awarded a Small Business Innovation Research (SBIR) grant to 712 North. The phase I SBIR grant supports the discovery and validation of small molecule OMA1 inhibitors. OMA1 is a mitochondrial protease whose activity correlates with mitochondrial distress and programmed cell death (apoptosis). Dr. Marcel V. Alavi, 712 North’s CEO, is the Principal Investigator on this SBIR grant. He shared, “I was so excited when I received the funding notice. This is a major achievement!" He continued, "The NIA has confidence in 712 North, and we will do everything within our power to make this SBIR project a success story.”

The NIA is one of the 27 Institutes and Centers of the National Institutes of Health (NIH). The NIA leads a broad scientific effort to understand the nature of aging and to extend the healthy, active years of life.

712 North is an R&D-stage therapeutics company focused on personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases. For more information, please visit www.712north.com.

712 North Inc. publishes a Mini Review with the title ‘Targeted OMA1 therapies for cancer’ in the International Journal of Cancer.

712 North Inc., an R&D-stage pharmaceutical company, announced on February 4, 2019 the publication of an overview article in the International Journal of Cancer with the title ‘Targeted OMA1 therapies for cancer.’ The article argues that the OMA1 mechanism of action represents the missing link between p53 and cytochrome c release. For more information, please visit www.712north.com.